Strong fit for a pre-seed AI/biotech startup with validated proof-of-concept. YC's network, compute credits, and biopharma connections align well with the venture's roadmap and EU/US ambitions. The founder's sole-founder status may be a minor concern, but the technology's clear SOTA advantage and named pharma partners strengthen the application.